CPI 300 - Coordination Pharmaceuticals
Alternative Names: CPI-300 - Coordination PharmaceuticalsLatest Information Update: 28 Jul 2024
At a glance
- Originator Coordination Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 15 Dec 2023 Coordination Pharmaceuticals completes a phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in USA (IV) (NCT04808453)
- 15 Jun 2021 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in USA (IV) (NCT04808453)